×
About 2,990 results

ALLMedicine™ Acid Phosphatase Center

Research & Reviews  1,113 results

Fin ray branching is defined by TRAP+ osteolytic tubules in zebrafish.
https://doi.org/10.1073/pnas.2209231119
Proceedings of the National Academy of Sciences of the Un... Cardeira-da-Silva J, Bensimon-Brito A et. al.

Nov 24th, 2022 - The shaping of bone structures relies on various cell types and signaling pathways. Here, we use the zebrafish bifurcating fin rays during regeneration to investigate bone patterning. We found that the regenerating fin rays form via two mineraliza...

Evaluation of culture conditions for osteoclastogenesis in RAW264.7 cells.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9671299
PloS One; Cheng Y, Liu H et. al.

Nov 18th, 2022 - Osteoclasts are the only multinucleated cells in vivo responsible for bone resorption and are vital for regulating bone remodeling and maintaining bone mass. The RAW264.7 cell line is widely used to study osteoclastic differentiation and biologica...

Compound of Cynanchum wilfordii and Humulus lupulus L. Ameliorates Menopausal Symptoms ...
https://doi.org/10.1007/s43032-022-01117-4
Reproductive Sciences (Thousand Oaks, Calif.); Kang HG, Kim HY et. al.

Nov 6th, 2022 - Cynanchum wilfordii and Humulus lupulus L. have been used for their various pharmacological properties in South Korea as a traditional medicine or health functional food, respectively, and their intake may relieve menopausal symptoms. The purpose ...

Reduced Bone Mass and Increased Osteocyte Tartrate-Resistant Acid Phosphatase (TRAP) Ac...
https://doi.org/10.1002/jbmr.4736
Journal of Bone and Mineral Research : the Official Journ... Wölfel EM, Lademann F et. al.

Nov 5th, 2022 - Hyperthyroidism causes secondary osteoporosis through favoring bone resorption over bone formation, leading to bone loss with elevated bone fragility. Osteocytes that reside within lacunae inside the mineralized bone matrix orchestrate the process...

Changes in bone biomarkers in response to different dosing regimens of cholecalciferol ...
https://doi.org/10.1007/s00467-022-05790-0
Pediatric Nephrology (Berlin, Germany); Kamath N, Iyengar A et. al.

Nov 3rd, 2022 - The effect of different dosing regimens of cholecalciferol supplementation on bone biomarkers has not been studied in children with chronic kidney disease (CKD). This is a post hoc analysis of a multi-center randomized controlled trial which inclu...

see more →

Drugs  3 results see all →

Clinicaltrials.gov  23 results

HB-302/HB-301 Therapy in Participants With Metastatic Castration-Resistant Prostate Cancer
https://clinicaltrials.gov/ct2/show/NCT05553639

Sep 23rd, 2022 - This is a first-in-human Phase 1/2, multinational, multicenter, open-label study of HB-302/HB-301 alternating 2-vector therapy in participants with metastatic castration-resistant prostate cancer (mCRPC) comprising 2 phases: a Phase 1 Dose Escalat...

pTVG-HP and Nivolumab in Patients With Non-Metastatic PSA-Recurrent Prostate Cancer
https://clinicaltrials.gov/ct2/show/NCT03600350

Sep 2nd, 2022 - The purpose of this study is to evaluate the safety of an investigational DNA vaccine, pTVG-HP, a plasmid DNA encoding human prostatic acid phosphatase (PAP), in combination with nivolumab, and the efficacy of this combination in decreasing serum ...

Assessment of TRACP-5b in Primary and Secondary Osteoporosis
https://clinicaltrials.gov/ct2/show/NCT05103592

Nov 15th, 2021 - Osteoporosis is a disease characterized by low bone density and a deterioration of bone microarchitecture that reduces bone strength and increases the risk of fracture. The hallmark of osteoporosis is the loss of both bone mineral and bone matrix....

Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer
https://clinicaltrials.gov/ct2/show/NCT02499835

Sep 29th, 2021 - PRIMARY OBJECTIVES: I. To evaluate the safety of pembrolizumab in combination with pTVG-HP (pTVG-HP plasmid DNA vaccine) in patients with castration-resistant, metastatic prostate cancer. II. To determine the 6-month progression-free survival and ...

Radiation Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Receiving Sipuleucel-T
https://clinicaltrials.gov/ct2/show/NCT01833208

Aug 5th, 2021 - PRIMARY OBJECTIVES: I. To assess whether radiation therapy (RT) increases the immunogenic potential or sipuleucel-T in participants with castration recurrent prostate cancer. II. To assess systemic changes to the immune system and genetic changes ...

see more →

News  57 results

The Orifices -- Where Most of Medicine's Money Is Made
https://www.medscape.com/viewarticle/983376

Nov 2nd, 2022 - Since antiquity, physicians have used their senses to study and try to understand human health and disease. Sight, sound, touch, smell, and taste. For much of history and for most physician-clinicians today, those five senses, when used well, are ...

Immunotherapeutics Aim for Larger Role in Prostate Cancer
https://www.onclive.com/view/immunotherapeutics-aim-for-larger-role-in-prostate-cancer

Jun 29th, 2022 - Highly effective tools, such as immunotherapeutic agents, have emerged for the treatment of patients with a wide range of malignancies. However, they have demonstrated relatively limited benefit in the treatment of patients with prostate cancer. I...

Renowned Prostate Cancer Experts Translate Research into Practice at the IPCC
https://www.onclive.com/view/ipcc_prostate_cancer

Mar 15th, 2022 - Click here to view as PDF. The Third Annual Interdisciplinary Prostate Cancer Congress (IPCC) took place March 27 in New York, New York. ArcMesa Educators organized the event, which was open to urologists, radiologists, and medical oncologists. S...

Immune Correlates May Indicate Responsiveness to Ipilimumab in mCRPC
https://www.onclive.com/view/immune-correlates-may-indicate-responsiveness-to-ipilimumab-in-mcrpc

Oct 6th, 2021 - Sumit Subudhi, MD, PhD A subset of patients with metastatic castration-resistant prostate cancer (mCRPC) who have low tumor mutational burden (TMB) may benefit from checkpoint inhibition with ipilimumab (Yervoy) if the tumor has a high density of...

Vogelzang Disputes 'Weak' Guideline Rating for Sipuleucel-T
https://www.onclive.com/view/vogelzang-disputes-weak-guideline-rating-for-sipuleucel-t

Oct 6th, 2021 - Nicholas J. Vogelzang, MD In a recent guideline for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC), the American Society of Clinical Oncology (ASCO) and Cancer Care Ontario (CCO) shared their thoughts on the imp...

see more →